Literature DB >> 31210309

JMJD3 enhances invasiveness and migratory capacity of non-small cell lung cancer cell via activating EMT signaling pathway.

Y Zhang1, P-Y Hua, C-Y Jin, J-D Li, G-X Zhang, B Wang.   

Abstract

OBJECTIVE: This study aimed to explore the expression of JMJD3 in non-small cell lung cancer (NSCLC) and to further study its association with clinical features and prognosis of patients. PATIENTS AND METHODS: Quantitative Real Time-Polymerase Chain Reaction (qRT-PCR) was performed to examine the level of JMJD3 in 46 pairs of NSCLC tissues and para-cancerous specimens. The relationship between JMJD3 level and clinical features of NSCLC and patients' prognosis was analyzed. And JMJD3 expression in NSCLC cells was further verified by qRT-PCR. In addition, JMJD3 knockdown model was constructed using siRNA in cell lines including A549 and SPC-A1, and the effect of JMJD3 on the biological function of NSCLC cells was analyzed by cell counting kit-8 (CCK-8) and transwell migration and invasive-ness assays. Lastly, Western blot was performed to explore the potential mechanism.
RESULTS: In this investigation, qRT-PCR results indicated that JMJD3 expression in above-mentioned tumor tissues was conspicuously higher than that in normal tissues. In addition, compared with patients with low level of JMJD3, patients with high level of JMJD3 had a higher incidence of lymphatic metastasis and distant metastasis and a lower overall survival rate. Meanwhile, the proliferation, invasiveness and migratory capacity of cells in the sh-JMJD3 group was conspicuously decreased when compared with the cells in negative control group. Western Blot results indicated that the levels of key proteins in EMT signaling pathway such as E-cadherin, N-cadherin, Vimentin, TGF-β, and MMP-9 were notably decreased in sh-JMJD3 group. Besides, the addition of TGF-β cytokines synergistically promoted the malignant progression of NSCLC induced by JMJD3.
CONCLUSIONS: JMJD3 expression was found conspicuously increased in NSCLC, which might be close relevant to NSCLC lymphatic or distant metastasis as well as patients' poor prognosis. Therefore, we speculated that JMJD3 could promote invasiveness and migratory capacity of non-small cell lung cancer cells by activating EMT process.

Entities:  

Year:  2019        PMID: 31210309     DOI: 10.26355/eurrev_201906_18063

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  8 in total

Review 1.  Emerging roles of JMJD3 in cancer.

Authors:  Maryam Farzaneh; Zeinab Kuchaki; Fatima Rashid Sheykhahmad; Seyed Mohammadmahdi Meybodi; Yusef Abbasi; Effat Gholami; Farhoodeh Ghaedrahmati; Omid Anbiyaee
Journal:  Clin Transl Oncol       Date:  2022-03-03       Impact factor: 3.405

2.  JMJD3 suppresses tumor progression in oral tongue squamous cell carcinoma patients receiving surgical resection.

Authors:  Yen-Hao Chen; Chang-Han Chen; Chih-Yen Chien; Yan-Ye Su; Sheng-Dean Luo; Shau-Hsuan Li
Journal:  PeerJ       Date:  2022-07-13       Impact factor: 3.061

3.  The Prognostic Significance Of JMJD3 In Primary Sarcomatoid Carcinoma Of The Lung, A Rare Subtype Of Lung Cancer.

Authors:  Shuman Li; Li Jiang; Qingmei He; Weidong Wei; Yun Wang; Xinke Zhang; Jun Liu; Keming Chen; Jiewei Chen; Dan Xie
Journal:  Onco Targets Ther       Date:  2019-11-07       Impact factor: 4.147

Review 4.  The Functions of the Demethylase JMJD3 in Cancer.

Authors:  Anna Sanchez; Fatma Zohra Houfaf Khoufaf; Mouhamed Idrissou; Frédérique Penault-Llorca; Yves-Jean Bignon; Laurent Guy; Dominique Bernard-Gallon
Journal:  Int J Mol Sci       Date:  2021-01-19       Impact factor: 5.923

5.  miR-146a-5p-mediated suppression on trophoblast cell progression and epithelial-mesenchymal transition in preeclampsia.

Authors:  Pingping Peng; Huamei Song; Chenghong Xie; Wenfei Zheng; Huigai Ma; Dandan Xin; Jingqiong Zhan; Xiaoqing Yuan; Aihua Chen; Jing Tao; Jufang Qin
Journal:  Biol Res       Date:  2021-09-13       Impact factor: 5.612

Review 6.  JMJD family proteins in cancer and inflammation.

Authors:  Wang Manni; Xue Jianxin; Hong Weiqi; Chen Siyuan; Shi Huashan
Journal:  Signal Transduct Target Ther       Date:  2022-09-01

7.  FOXH1 promotes lung cancer progression by activating the Wnt/β-catenin signaling pathway.

Authors:  Jun Zhang; Xian Zhang; Shasha Yang; Yanqiu Bao; Dongyuan Xu; Lan Liu
Journal:  Cancer Cell Int       Date:  2021-06-05       Impact factor: 5.722

Review 8.  KDM6 Demethylases and Their Roles in Human Cancers.

Authors:  Chunyan Hua; Jiaqing Chen; Shuting Li; Jianan Zhou; Jiahong Fu; Weijian Sun; Wenqian Wang
Journal:  Front Oncol       Date:  2021-12-07       Impact factor: 6.244

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.